Skip to main content
. 2022 Jan 28;88(6):2875–2884. doi: 10.1111/bcp.15191

FIGURE 3.

FIGURE 3

Drug target MR effects of IL‐6 and IL‐6R on clinical outcome, per 1 mg/L reduction in CRP. Forest plots representing the risk of clinical outcome parameters for all genetic instruments, scaled to a 1 mg/L reduction in CRP levels. The hash mark indicates an association of the genetic instrument with the clinical outcome that meets the multiple testing threshold (8.92 × 10−4)